ACTIVE_NOT_RECRUITING

Hyperbaric Oxygen Treatment (HBOT) During Methadone Tapering

Talk to us

Conditions

Opioid Use Disorder

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The aims of this study are to 1) explore the efficacy of hyperbaric oxygen therapy (HBOT) applied at two different pressures compared to sham treatment in relieving signs and symptoms (both physical and psychological) of opioid withdrawal in human subjects associated with methadone dose reductions; and 2): explore whether HBOT can increase the odds of successful methadone dose reduction in patients who are interested in tapering their opioid dose. The investigators aim to explore, through qualitative methods, individual's experiences with treatment for opioid use disorder (OUD).

Official Title

Hyperbaric Oxygen Treatment (HBOT) During Methadone Tapering in Human Subjects With Opioid Use Disorder

Quick Facts

Study Start:2023-12-04
Study Completion:2025-12-30
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:ACTIVE_NOT_RECRUITING

Study ID

NCT05924022

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Enrollment in a supervised opioid treatment program at the Spokane Regional Health District
  2. * Age greater than 18 years
  3. * Ability to read, speak, and write English
  4. * Ability to provide written informed consent.
  1. * Pregnancy
  2. * Any other medical or psychiatric condition that the PI, Co-PI (physician of record) or the Spokane Hyperbaric Center medical director determine might compromise safe study participation in the HBOT clinic (including but not limited to active psychosis, history of frequent psychiatric hospitalizations, severe anxiety with claustrophobia, aggression)
  3. * Upper respiratory infection
  4. * Emphysema
  5. * Air cysts in the lung
  6. * History of thoracic or ear surgery
  7. * Taking the medication Antabuse for alcohol addiction
  8. * High fever.

Contacts and Locations

Principal Investigator

Layton Matt, MD
PRINCIPAL_INVESTIGATOR
Washington State University

Study Locations (Sites)

Spokane Regional Health District
Spokane, Washington, 99201
United States

Collaborators and Investigators

Sponsor: Washington State University

  • Layton Matt, MD, PRINCIPAL_INVESTIGATOR, Washington State University

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2023-12-04
Study Completion Date2025-12-30

Study Record Updates

Study Start Date2023-12-04
Study Completion Date2025-12-30

Terms related to this study

Additional Relevant MeSH Terms

  • Opioid Use Disorder